SCHEDULE: Deep Track Capital Takes 5.02% Stake in Bicara Therapeutics

Deep Track Capital, LP and affiliates reported a 5.02% beneficial ownership stake in Bicara Therapeutics Inc., holding 2,750,000 common shares.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively reported beneficial ownership of 2,750,000 shares of Bicara Therapeutics Inc. common stock.
• This represents 5.02% of the outstanding common stock of Bicara Therapeutics Inc.
• The shares were acquired by institutional investors and are not held for the purpose of changing or influencing control of the issuer.
• The filing was made under Rule 13d-1(b), indicating a passive investment intent.
• The percentage of class was calculated based on 54,781,850 shares outstanding as of November 5, 2025, as reported by the issuer on its 10-Q filed with the SEC on November 10, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a specialized biotech fund taking a 5.02% stake suggests confidence in Bicara Therapeutics' prospects without indicating an activist intent.

Positives

• A significant institutional investor, Deep Track Capital, has taken a substantial 5.02% stake in Bicara Therapeutics, potentially signaling confidence in the company's future prospects.
• The filing indicates a passive investment intent, suggesting the investor is not seeking to disrupt current management or strategy.

Risks

• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating risks related to activist investor intervention.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Bicara Therapeutics Inc.'s future operations or financial performance.

Management Comments

• Certifications from David Kroin, Managing Member of Deep Track Capital, LP, state that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that a 5.02% stake by a specialized biotechnology investment firm like Deep Track Capital can be viewed positively in the biotech sector. Such an investment often signals a thorough due diligence process and a belief in the long-term potential of the company's pipeline or technology, especially for a clinical-stage company like Bicara Therapeutics. This move could attract further investor attention to Bicara Therapeutics, which operates in a high-risk, high-reward industry.

Comparison to Industry Standards

• StockSavvy.ai observes that institutional investors frequently take significant stakes in promising biotechnology companies, often exceeding the 5% threshold that triggers a Schedule 13G filing.
• While specific comparable companies or projects are not detailed in this filing, a 5% stake by a dedicated biotech fund like Deep Track Capital is a standard practice for funds seeking exposure to innovative therapies.
• Similar stakes are often seen in early to mid-stage biopharmaceutical companies where institutional capital is crucial for funding research and development, such as investments by funds like RA Capital Management or Orbimed in emerging biotech firms.

Stakeholder Impact

• Shareholders: May view the investment as a vote of confidence, potentially leading to increased investor interest and share price stability.
• Management: The passive nature of the investment suggests no immediate pressure for strategic or operational changes from this investor.

Next Steps

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin will continue to monitor their investment in Bicara Therapeutics Inc.
• Further Schedule 13G or 13D filings would be required if their ownership percentage significantly changes or if their investment intent shifts to influencing control.

Key Dates

Recommendation

A significant stake by a specialized biotech fund like Deep Track Capital is generally a positive indicator, suggesting a belief in the company's long-term value. However, this filing alone does not provide new operational or financial performance data to warrant an immediate 'buy' recommendation. It primarily signals institutional interest. Investors should 'hold' and monitor future company developments and financial reports for more comprehensive insights into Bicara Therapeutics' intrinsic value and operational progress.

Keywords

Bicara Therapeutics, Deep Track Capital, Biotechnology, SEC Filing, Schedule 13G, Beneficial Ownership, Institutional Investment, Common Stock, Biotech